Graybug Vision (GRAY) Competitors

iBio (NYSE:IBIO) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Which has stronger earnings & valuation, IBIO or GRAY?

iBio has higher revenue and earnings than Graybug Vision. iBio is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$400K	41.96	-$24.91M	-$1.74	-0.49
Graybug Vision	N/A	N/A	-$35.60M	-$24.23	-0.13

Does the media favor IBIO or GRAY?

In the previous week, iBio had 1 more articles in the media than Graybug Vision. MarketBeat recorded 1 mentions for iBio and 0 mentions for Graybug Vision. iBio's average media sentiment score of 0.49 beat Graybug Vision's score of 0.00 indicating that iBio is being referred to more favorably in the media.

Company	Overall Sentiment
iBio	Neutral
Graybug Vision	Neutral

Is IBIO or GRAY more profitable?

iBio's return on equity of -73.15% beat Graybug Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-73.15%	-45.51%
Graybug Vision	N/A	-77.61%	-71.34%

Do insiders and institutionals believe in IBIO or GRAY?

7.9% of iBio shares are held by institutional investors. Comparatively, 49.9% of Graybug Vision shares are held by institutional investors. 0.6% of iBio shares are held by insiders. Comparatively, 7.9% of Graybug Vision shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more risk and volatility, IBIO or GRAY?

iBio has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Do analysts prefer IBIO or GRAY?

iBio currently has a consensus target price of $5.00, suggesting a potential upside of 485.48%. Given iBio's stronger consensus rating and higher probable upside, analysts plainly believe iBio is more favorable than Graybug Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

iBio beats Graybug Vision on 11 of the 14 factors compared between the two stocks.